
    
      This is a 90-day, explanatory; randomized; open-label, 2-arm; parallel group with blinded
      outcome evaluation study exploring the efficacy and study of early rosuvastatin 20 mg/d
      treatment in acute ischemic patients with stroke onset in 24 hours.
    
  